What is LyGenesis?
LyGenesis is a clinical-stage cell therapy company dedicated to transforming the landscape of organ replacement. Its core technology utilizes an outpatient endoscopic ultrasound procedure to deliver therapeutic cells into a patient's lymph nodes, effectively turning them into functional ectopic organs. This methodology offers a compelling alternative to traditional, high-risk organ transplants, potentially reducing both the economic burden on healthcare systems and the physical trauma experienced by patients. By focusing on the intersection of synthetic biology and clinical medicine, LyGenesis is actively working to improve patient outcomes for those suffering from chronic, end-stage organ failure.
How much funding has LyGenesis raised?
LyGenesis has raised a total of $34M across 3 funding rounds:
Debt
$4M
Debt
$11M
Series A
$19M
Debt (2019): $4M with participation from Juvenescence, Ltd. and Longevity Vision Fund
Debt (2020): $11M led by Juvenescence Limited and Longevity Vision Fund
Series A (2023): $19M supported by Prime Movers Lab and Juvenescence
Key Investors in LyGenesis
Prime Movers Lab
Prime Movers Lab is a venture capital firm that focuses on funding breakthrough scientific startups aimed at transforming industries and improving lives.
Juvenescence
Juvenescence is a life sciences company focused on developing innovative therapies aimed at modifying the aging process and extending healthy human lifespan.
Longevity Vision Fund
An investment firm specializing in the longevity and biotechnology sectors, supporting companies that aim to extend human health span.
What's next for LyGenesis?
With the recent infusion of capital, LyGenesis is well-positioned to accelerate its clinical trial pipeline and refine its therapeutic delivery mechanisms. The company's strategic roadmap focuses on validating its ectopic organ technology across multiple indications, moving closer to commercial viability. As it transitions into more advanced clinical phases, the firm will likely prioritize regulatory milestones and the expansion of its manufacturing capabilities. The backing from specialized life sciences investors suggests a long-term commitment to scaling this breakthrough technology, which could fundamentally alter the standard of care for patients awaiting organ transplants globally.
See full LyGenesis company page
